Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms

The rate of lymphoproliferative disorders amongMPN patients was low (24/3069 0.78%) but higher than expected inthe general population and was not associated with a previous expo-sure to ruxolitinib. As none of our patients showed B-cell clonality onperipheral blood before ruxolitinib treatment, our findings reinforcethe view that in the absence of B cell clones, ruxolitinib treatmentmay be considered relatively safe and can be initiated with close mon-itoring. The use of ruxolitinib in case of preexisting B-cell clonalityneeds further prospective studies.